




The relative strengths and weaknesses of Cymabay Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cymabay Therapeutics Inc compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 144% points. The greatest weakness of Cymabay Therapeutics Inc is the variable Research and Development, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 348%, being 110% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	202,923
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,636
Liabilities, Non-Current	1,743
Other Assets	395
Other Compr. Net Income	138
Other Expenses	5,075
Other Liabilities	0
Other Net Income	5,342
Other Revenues	0
Property and Equipment	2,409
Research and Development	83,837
Selling, General and Administrative Expense	19,238

Output Variable	Value in 1000 USD
Assets	205,727
Liabilities	19,379
Expenses	108,150
Revenues	0
Stockholders Equity	186,348
Net Income	-102,808
Comprehensive Net Income	-102,739
BaseVar	169,368
ECR before Limited Liability	270%
Economic Capital Ratio	348%